IVASWIFT 7.5 (IVABRADINE TABLETS 7.5MG)

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

Ivabradine Oxalate

Boleh didapati daripada:

SYNERRV SDN BHD

INN (Nama Antarabangsa):

Ivabradine Oxalate

Unit dalam pakej:

4 x 14 Tablets

Dikeluarkan oleh:

IND-SWIFT LIMITED

Risalah maklumat

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
IVASWIFT 5 (IVABRADINE TABLETS 5MG)
IVASWIFT 7.5 (IVABRADINE TABLETS
7.5MG)
_Ivabradine Tablets (5mg, 7.5mg) _
_ _
1
WHAT IS IN THIS LEAFLET
1.
What IVASWIFT is used for
2.
How IVASWIFT works
3.
Before you use IVASWIFT
4.
How to use IVASWIFT
5.
While you are using it
6.
Side effects
7.
Storage
and
Disposal
of
IVASWIFT
8.
Product Description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of revision
WHAT IVASWIFT IS USED FOR
IVASWIFT (ivabradine) is a heart
medicine used to treat:
-
Symptomatic
stable
angina
pectoris (which causes chest pain)
in adult patients whose heart rate is
over
or
equal
to
70
beats
per
minute. It is used in adult patients
who do not tolerate or cannot take
heart
medicines
called
beta-
blockers
(medicine
that
controls
heart
rate).
It
is
also
used
in
combination with beta- blockers in
adult patients whose condition is
not fully controlled with a beta-
blocker.
-
Chronic heart failure in adult
patients whose heart rate is over or
equal to 75 beats per minute. It is
used in combination with standard
therapy,
including
beta-
blocker
therapy or when beta- blockers are
contraindicated or not tolerated.
_About _
_stable _
_angina _
_pectoris _
_(usually referred to as “angina”): _
Stable
angina
is
a
heart
disease
which happens when the heart does
not
receive
enough
oxygen.
It
usually appears between 40 and 50
years of age. The most common
symptom of angina is chest pain or
discomfort. Angina is more likely
to
happen
when
the
heart
beats
faster in situations such as exercise,
emotion, exposure to the cold or
after eating. This increase in heart
rate can cause the chest pain in
people who suffer from angina.
_About chronic heart failure: _
Chronic heart failure is a heart
disease which happens when your
heart cannot pump enough blood
to the rest of your body. The most
common symptoms of heart failure
are breathlessness, fatigue,
tiredness and ankle swelling.
HOW IVASWIFT WORKS
IVASWIFT
mainly
works
by
reducing the heart rate by a few
be

Ciri produk

IVASWIFT 5 (IVABRADINE TABLETS 5MG)
IVASWIFT 7.5 (IVABRADINE TABLETS 7.5MG)
COMPOSITION
IVASWIFT 5 (IVABRADINE TABLETS 5MG)
Each film coated tablet contains: Ivabradine Oxalate equivalent to
Ivabradine 5mg Excipients q.s.
Color: Iron Oxide Red and Iron Oxide Yellow
IVASWIFT 7.5 (IVABRADINE TABLETS 7.5MG)
Each film coated tablet contains: Ivabradine Oxalate equivalent to
Ivabradine 7.5mg Excipients q.s.
Color: Iron Oxide Red and Iron Oxide Yellow
PRODUCT DESCRIPTION
IVASWIFT 5 (IVABRADINE TABLETS 5MG) : Salmon colored, oblong shaped,
biconvex, film coated tablets,
with one side breakline and plain on other side.
IVASWIFT 7.5 (IVABRADINE TABLETS 7.5MG) : Salmon colored, arc
triangular shaped, biconvex, film
coated tablets, plain on both sides.
PHARMACODYNAMICS
Pharmacotherapeutic group:
Cardiac therapy, other cardiac preparations, ATC code: C01EB17
Mechanism of Action
Ivabradine is a pure heart rate lowering agent, acting by selective
and specific inhibition of the
cardiac pacemaker If current that controls the spontaneous diastolic
depolarisation in the sinus node
and regulates heart rate. The cardiac effects are specific to the
sinus node with no effect on intra-
atrial, atrioventricular or intraventricular conduction times, nor on
myocardial contractility or
ventricular repolarisation.
Ivabradine can interact also with the retinal current Ih which closely
resembles cardiac If. It
participates in the temporal resolution of the visual system, by
curtailing the retinal response to
bright light stimuli. Under triggering circumstances (e.g. rapid
changes in luminosity), partial
inhibition of Ih by ivabradine underlies the luminous phenomena that
may be occasionally
experienced by patients. Luminous phenomena (phosphenes) are described
as a transient enhanced
brightness in a limited area of the visual field.
Pharmacodynamic effects
The main pharmacodynamic property of ivabradine in humans is a
specific dose dependent
reduction in heart rate. Analysis of heart rate reduction with doses
up to 20 mg twice daily indicates